Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2026)

Keros Therapeutics (KROS) has 7 years of Cash & Equivalents data on file, last reported at $287.4 million in Q4 2025.

• Quarterly Cash & Equivalents fell 48.67% year-over-year to $287.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $287.4 million (down 48.67% YoY) and the FY2025 annual result came in at $287.4 million, down 48.67% from the prior year.
• Cash & Equivalents slipped to $287.4 million in Q4 2025, from $693.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $720.5 million in Q1 2025 to a low of $215.6 million in Q2 2022.
• A 5-year average of $376.5 million and a median of $305.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 368.11% — and 2025, when it sank 48.67%.
• Tracing KROS's Cash & Equivalents over 5 years: stood at $230.0 million in 2021, then increased by 21.3% to $279.0 million in 2022, then climbed by 18.67% to $331.1 million in 2023, then soared by 69.09% to $559.9 million in 2024, then slumped by 48.67% to $287.4 million in 2025.
• The last three Cash & Equivalents figures came in at $287.4 million (Q4 2025), $693.5 million (Q3 2025), and $690.2 million (Q2 2025), per Business Quant data.